June 16, 2011 – The Food and Drug Administration (FDA) should not mandate comparative effectiveness trials as part of the drug approval process, according to Scott Gottleib, a resident fellow with the American Enterprise Institute for Public Policy Research (AEI). Gottleib, a former FDA policy head, writes in AEI’s June issue of Health Policy Outlook […]
Read more